Enclomiphene Citrate International Purchase Legalities: What You Need to Know in 2026

Is enclomiphene approved in the US or Europe?

No. FDA's briefing material for its June 2022 advisory committee states plainly that no FDA-approved drugs contain enclomiphene as an active ingredient [1].

In Europe, EMA's Committee for Medicinal Products for Human Use adopted a negative opinion on 25 January 2018 recommending refusal of a marketing authorisation for EnCyzix (enclomifene), applied for by Renable Pharma Limited, for hypogonadotropic hypogonadism in overweight men with a BMI of at least 25 [3]. The committee's reasons were that the studies showed higher testosterone but did not examine whether symptoms such as bone strength, weight gain, impotence or libido improved, and that there was a risk of venous thromboembolism. The assessment rested on four main studies in 588 patients [3].

Why FDA did not approve it

The sponsor, Repros Therapeutics, filed an application for enclomiphene (Androxal) for secondary hypogonadism in fertile men. In 2015 the company announced a complete response letter, which FDA summarises as saying that the design of the phase 3 studies was not adequate to demonstrate clinical benefit, with concerns about study entry criteria, titration and bioanalytical method validation [1]. No approval has followed [1].

FDA's May 2018 guidance on secondary hypogonadism says it is unclear whether raising testosterone in this population gives clinical benefit, that trials should show meaningful improvement in at least one symptom or sign, and that semen-parameter changes alone are not enough to establish efficacy [1]. The phase 3 programme measured testosterone, LH, FSH and sperm counts rather than symptom or quality-of-life improvement, and both FDA and EMA identified that as a gap [1].

A 2026 British Society of Sexual Medicine position statement records that enclomiphene is not approved by FDA or EMA, that its manufacturer discontinued development in 2021, and that it should be used only by experienced clinicians in specialist or research settings because long-term efficacy and safety data are lacking [7].

What FDA's personal-importation policy says

FDA's import page states that in most circumstances it is illegal for individuals to import drugs into the US for personal use, and that if a drug is approved for use in another country but is an unapproved new drug in the US, it is illegal to import [2]. FDA also says it cannot ensure the safety and effectiveness of medicine bought over the internet from foreign sources [2].

FDA personnel may consider a more permissive decision in defined situations. One is a product not for treatment of a serious condition where there is no known significant health risk. The other is a serious condition for which effective treatment may not be available domestically, where the product is not commercialised or promoted to US residents, does not represent an unreasonable risk, the consumer affirms in writing that it is for personal use, the quantity is generally not more than a three-month supply, and the consumer provides either the name and address of the US doctor responsible for treatment or evidence that the product continues a treatment begun abroad [2]. That wording describes discretion FDA personnel may exercise, not an entitlement for any particular drug.

What about compounded enclomiphene inside the US?

Because enclomiphene has no FDA-approved product, no USP monograph, and is not on FDA's final list of bulk substances that can be used in compounding, pharmacies cannot simply compound it as a routine matter [4]. FDA's list, updated 14 May 2026, places enclomiphene citrate in Category 1, 'Bulk Drug Substances Under Evaluation' [4]. FDA says it does not intend to take action against a compounder using a Category 1 substance if the conditions in its guidance are met; that is an enforcement-discretion policy, not an approval and not a finding that the product is safe or effective [4].

At the 8 June 2022 meeting of FDA's Pharmacy Compounding Advisory Committee, FDA proposed that enclomiphene citrate not be added to the list of allowed bulk substances. The committee voted 4 yes, 8 no, 0 abstentions, with members who voted no citing a lack of clinical efficacy evidence [5].

Enclomiphene is not on FDA's Category 2 list of bulk substances that may present significant safety risks [8]. Compounded enclomiphene products have not been reviewed by FDA for safety, effectiveness or quality [8].

Is clomiphene the same as enclomiphene?

No. Clomiphene citrate is a mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), and the USP monograph gives enclomiphene content of clomiphene as 50 to 70 percent [1]. Clomiphene itself is FDA-approved, but only for ovulatory dysfunction in women who want to become pregnant [9]. Its label has no male indication, states that there are no adequate or well-controlled studies demonstrating effectiveness in male infertility, and notes that testicular tumors and gynecomastia have been reported in men using clomiphene, with cause and effect not known [9].

The clomiphene label warns that blurring or other visual symptoms such as spots or flashes may occur, that they are usually reversible, and that prolonged visual disturbances have been reported [9]. These label warnings apply to the clomiphene mixture and have not been established for enclomiphene alone.

Is it prohibited in sport?

WADA's 2026 Prohibited List places clomifene in class S4, Hormone and Metabolic Modulators, prohibited at all times, under S4.2 anti-estrogenic substances and SERMs [6]. Enclomiphene is not named separately, but the list is 'including, but not limited to', and enclomiphene is an isomer of clomifene, so athletes should treat it as prohibited and check with their anti-doping organisation [6].

What the drug is and what trials showed

Enclomiphene is an oral selective estrogen receptor modulator. It blocks estrogen receptors in the pituitary, so the pituitary releases more LH and FSH, which signals the testes to make more testosterone and keep making sperm [1].

No approved dose exists. A 6-week phase 2 dose-finding trial used 6.25, 12.5 and 25 mg once daily [10], and the phase 3 protocols used 12.5 mg daily, up-titrated to 25 mg at week 6 if morning testosterone stayed below 300 ng/dL [11].

In two parallel phase 3 studies against AndroGel 1.62% in overweight men with secondary hypogonadism, total testosterone rose in all treatment groups over 16 weeks, LH and FSH rose with enclomiphene and fell with testosterone gel, and sperm concentration stayed in the normal range on enclomiphene while there was a marked reduction in spermatogenesis on the gel [12]. A 2025 meta-analysis of randomized trials of SERMs, clomiphene and enclomiphene combined, found total testosterone higher than placebo by a mean 273.76 ng/dL (95% CI 191.87 to 355.66) with high heterogeneity, and no significant difference versus testosterone gel [13].

The safety record is short. When FDA reviewed the nomination in 2022 it listed, from published trials, FDA adverse event reports and EMA's review: cardiac and thromboembolic events including pulmonary embolism and deep vein thrombosis in a safety study, raised estradiol, raised PSA, raised hematocrit, and no long-term safety data [1]. EMA noted a slightly higher rate of cardiac and thromboembolic events than with testosterone, and cataracts in nonclinical studies, and wanted ocular monitoring [1]. In the 12-week ZA-302 study, headache occurred in 7 of 112 men on 12.5 mg versus 1 of 47 on placebo, and nausea in 4 of 112 versus 3 of 47 [14].